CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-07-20 | Ring Christine General Counsel | Sale | −1,200 | $27.00 | $32K | 805 |
| 2021-07-20 | Ring Christine General Counsel | Exercise or conversion · Employee Stock Option (right to buy) | −1,200 | 112,066 | ||
| 2021-07-12 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +7,500 | $1.11 | $8K | 11,830 |
| 2021-07-12 | Beaurang Pierre Chief Business Officer | Sale | −7,100 | $23.88 | $170K | 4,730 |
| 2021-07-12 | Beaurang Pierre Chief Business Officer | Sale | −400 | $24.73 | $10K | 4,330 |
| 2021-07-12 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −7,500 | 14,062 | ||
| 2021-07-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +400 | $7.26 | $3K | 14,204 |
| 2021-07-01 | Hansen Gwenn Chief Scientific Officer | Sale | −400 | $26.76 | $11K | 13,804 |
| 2021-07-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −400 | 71,866 | ||
| 2021-06-10 | Ring Christine General Counsel | Exercise or conversion | +1,200 | $1.86 | $2K | 2,005 |
| 2021-06-10 | Ring Christine General Counsel | Sale | −1,000 | $29.18 | $29K | 1,005 |
| 2021-06-10 | Ring Christine General Counsel | Sale | −200 | $30.52 | $6K | 805 |
| 2021-06-10 | Ring Christine General Counsel | Exercise or conversion · Employee Stock Option (right to buy) | −1,200 | 113,266 | ||
| 2021-06-10 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +7,500 | $1.11 | $8K | 11,830 |
| 2021-06-10 | Beaurang Pierre Chief Business Officer | Sale | −6,000 | $29.15 | $175K | 5,830 |
| 2021-06-10 | Beaurang Pierre Chief Business Officer | Sale | −1,100 | $30.01 | $33K | 4,730 |
| 2021-06-10 | Beaurang Pierre Chief Business Officer | Sale | −400 | $30.90 | $12K | 4,330 |
| 2021-06-10 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −7,500 | 21,562 | ||
| 2021-06-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +400 | $7.26 | $3K | 14,204 |
| 2021-06-01 | Hansen Gwenn Chief Scientific Officer | Sale | −400 | $27.74 | $11K | 13,804 |
Page 33 of 42 · 829 trades